Limits...
Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.

Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, Wang Q, Zhou WJ, Hu W, Yang HH, Xu HH, Yan WH - J. Cell. Mol. Med. (2010)

Bottom Line: HLA-G has been documented both in establishment of anti-tumour immune responses and in tumour evasion.Patient plasma sHLA-G level (≥median, 32.0 U/ml) had a significantly shorter survival time (P= 0.044); however, no similar significance was observed for the lesion HLA-G expression.In vitro data showed that both cell surface HLA-G and patient plasma sHLA-G could dramatically decrease the NK cell cytolysis.

View Article: PubMed Central - PubMed

Affiliation: Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Linhai, Zhejiang, China.

Show MeSH

Related in: MedlinePlus

Plasma sHLA-G levels in normal and NSCLC patients, and its correlation with clinical stage. (A) Comparison of plasma sHLA-G between NSCLC patients and normal controls. Plasma sHLA-G concentrations from 91 NSCLC patients (median: 34.0 U/ml, range: 3.13–275.5) were significantly higher (P= 0.004) than those detected in 150 age-matched healthy controls (median: 20.4 U/ml, range: 0.97–270.6). (B) Correlation between patient plasma sHLA-G levels and clinical disease stage. Plasma sHLA-G level in different clinical stage of NSCLC patients is 25.3 U/ml (range: 3.13–155.9) for Stage I, 22.3 U/ml (range: 3.27–243.6) for Stage II, 34.3 U/ml (range: 3.46– 275.5) for Stage III and 56.6 U/ml (range: 3.13–223.5) for Stage IV, respectively. NSCLC patient plasma sHLA-G level in Stage IV was significantly higher than that in Stage I (P= 0.025) and Stage II (P= 0.029), respectively.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822572&req=5

fig02: Plasma sHLA-G levels in normal and NSCLC patients, and its correlation with clinical stage. (A) Comparison of plasma sHLA-G between NSCLC patients and normal controls. Plasma sHLA-G concentrations from 91 NSCLC patients (median: 34.0 U/ml, range: 3.13–275.5) were significantly higher (P= 0.004) than those detected in 150 age-matched healthy controls (median: 20.4 U/ml, range: 0.97–270.6). (B) Correlation between patient plasma sHLA-G levels and clinical disease stage. Plasma sHLA-G level in different clinical stage of NSCLC patients is 25.3 U/ml (range: 3.13–155.9) for Stage I, 22.3 U/ml (range: 3.27–243.6) for Stage II, 34.3 U/ml (range: 3.46– 275.5) for Stage III and 56.6 U/ml (range: 3.13–223.5) for Stage IV, respectively. NSCLC patient plasma sHLA-G level in Stage IV was significantly higher than that in Stage I (P= 0.025) and Stage II (P= 0.029), respectively.

Mentions: Plasma sHLA-G levels in 91 NSCLC patients and 150 normal healthy individuals were determined by ELISA. Concentration of the plasma sHLA-G was with the median of 34.0 U/ml (range: 3.13– 275.5) for NSCLC patients, 20.4 U/ml (range: 0.97–270.6) for normal controls, respectively. Data revealed that sHLA-G expression in NSCLC patients was significantly higher than that in normal controls (P= 0.004) (Fig. 2A).


Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.

Lin A, Zhu CC, Chen HX, Chen BF, Zhang X, Zhang JG, Wang Q, Zhou WJ, Hu W, Yang HH, Xu HH, Yan WH - J. Cell. Mol. Med. (2010)

Plasma sHLA-G levels in normal and NSCLC patients, and its correlation with clinical stage. (A) Comparison of plasma sHLA-G between NSCLC patients and normal controls. Plasma sHLA-G concentrations from 91 NSCLC patients (median: 34.0 U/ml, range: 3.13–275.5) were significantly higher (P= 0.004) than those detected in 150 age-matched healthy controls (median: 20.4 U/ml, range: 0.97–270.6). (B) Correlation between patient plasma sHLA-G levels and clinical disease stage. Plasma sHLA-G level in different clinical stage of NSCLC patients is 25.3 U/ml (range: 3.13–155.9) for Stage I, 22.3 U/ml (range: 3.27–243.6) for Stage II, 34.3 U/ml (range: 3.46– 275.5) for Stage III and 56.6 U/ml (range: 3.13–223.5) for Stage IV, respectively. NSCLC patient plasma sHLA-G level in Stage IV was significantly higher than that in Stage I (P= 0.025) and Stage II (P= 0.029), respectively.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822572&req=5

fig02: Plasma sHLA-G levels in normal and NSCLC patients, and its correlation with clinical stage. (A) Comparison of plasma sHLA-G between NSCLC patients and normal controls. Plasma sHLA-G concentrations from 91 NSCLC patients (median: 34.0 U/ml, range: 3.13–275.5) were significantly higher (P= 0.004) than those detected in 150 age-matched healthy controls (median: 20.4 U/ml, range: 0.97–270.6). (B) Correlation between patient plasma sHLA-G levels and clinical disease stage. Plasma sHLA-G level in different clinical stage of NSCLC patients is 25.3 U/ml (range: 3.13–155.9) for Stage I, 22.3 U/ml (range: 3.27–243.6) for Stage II, 34.3 U/ml (range: 3.46– 275.5) for Stage III and 56.6 U/ml (range: 3.13–223.5) for Stage IV, respectively. NSCLC patient plasma sHLA-G level in Stage IV was significantly higher than that in Stage I (P= 0.025) and Stage II (P= 0.029), respectively.
Mentions: Plasma sHLA-G levels in 91 NSCLC patients and 150 normal healthy individuals were determined by ELISA. Concentration of the plasma sHLA-G was with the median of 34.0 U/ml (range: 3.13– 275.5) for NSCLC patients, 20.4 U/ml (range: 0.97–270.6) for normal controls, respectively. Data revealed that sHLA-G expression in NSCLC patients was significantly higher than that in normal controls (P= 0.004) (Fig. 2A).

Bottom Line: HLA-G has been documented both in establishment of anti-tumour immune responses and in tumour evasion.Patient plasma sHLA-G level (≥median, 32.0 U/ml) had a significantly shorter survival time (P= 0.044); however, no similar significance was observed for the lesion HLA-G expression.In vitro data showed that both cell surface HLA-G and patient plasma sHLA-G could dramatically decrease the NK cell cytolysis.

View Article: PubMed Central - PubMed

Affiliation: Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Linhai, Zhejiang, China.

Show MeSH
Related in: MedlinePlus